SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

The population of cancer survivors is rapidly increasing due to improving healthcare.
However, cancer therapies often have long-term side effects. One example is cancer therapy …

Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …

Simple Summary Despite significant advances in the treatment of cancer, it remains a major
cause of death worldwide and new treatment options are constantly being sought. An …

Canagliflozin (Cana), an anti-diabetes drug belongs to sodium-glucose cotransporter 2
inhibitor, is gaining interest because of its extra cardiovascular benefits. Ferroptosis is a new …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Background Nonalcoholic fatty liver disease (NAFLD) is closely associated with
Cardiovascular disease (CVD). We aim to examine the association of Life's Essential 8 …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among
patients with established heart failure. Despite supportive basic science studies, there are …

Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …